The lowest recommended dose should be used initially, accompanied by regular monitoring of clinical response. 9.3.1. Acute Treatment: Recommendations IIb B-NR 2. Oral dofetilide may be reasonable for prevention of recurrent AT or atrial flutter in ACHD patients.447,474,487,488 See Online Data Supplement 20. Two small observational studies on the use of oral dofetilide for ACHD patients report a high rate of acute conversion of AT or atrial flutter, with longer-term efficacy of the drug (defined by either complete suppression or partial improvement of symptoms) ranging from 70% to 85%. The benefit was tempered by an association with torsades de pointes in 10%.471,484 Although many patients continued to experience recurrence, these episodes were better tolerated and were of limited duration.471,484 Because of the potential risk of proarrhythmia, dofetilide is usually a second-line medication after failure of beta blockers and sotalol. Initiation of oral dofetilide is recommended during 72-hour inpatient monitoring. IIb B-NR Amiodarone may be reasonable for prevention of recurrent AT or atrial flutter in ACHD patients for whom other medications and catheter ablation are ineffective or contraindicated.447 See Online Data Supplement 20. An observational study reported efficacy of amiodarone in maintaining sinus rhythm, although side effects were noted frequently, including thyroid disorders or AV block.447 The risk of significant side effects increases with chronic use and with higher dosages; using the minimal effective chronic dosage is recommended. Observational studies reported thyroid disorders in 13% to 36% of ACHD patients receiving amiodarone; risk factors for thyrotoxicosis include female sex, cyanotic heart disease, low body mass index, prior Fontan procedure, or dosages >200 mg daily.511,512 Amiodarone is recommended for short-term use or for patients for whom alternative therapy is not an option for prevention of recurrent AT. III: Harm B-NR 1.


Observational studies reported thyroid disorders in 13% to 36% of ACHD patients receiving amiodarone; risk factors for thyrotoxicosis include female sex, cyanotic heart disease, low body mass index, prior Fontan procedure, or dosages >200 mg daily.511,512 Amiodarone is recommended for short-term use or for patients for whom alternative therapy is not an option for prevention of recurrent AT. III: Harm B-NR 1. Flecainide should not be administered for treatment of SVT in ACHD patients and significant ventricular dysfunction.419 See Online Data Supplement 20. There are no RCTs on the use of flecainide in ACHD patients and ventricular dysfunction. One retrospective study collected data on 579 young patients, 369 of whom received flecainide for the treatment of SVT. Efficacy for the treatment of SVT was 71%. Among 12 patients with cardiac arrest while receiving flecainide for SVT, 8 had congenital heart disease, and 7 of 8 had either mild to moderate ventricular dysfunction or systemic right- or single-ventricle anatomy. The risk associated with flecainide treatment of SVT associated with congenital heart disease appears to be highest among patients with complex heart disease or ventricular dysfunction. Recommendations for Ongoing Management of SVT in ACHD Patients (Continued) COR LOE Recommendations Recommendations for Acute Treatment of SVT in Pregnant Patients COR LOE Recommendations I C-LD 1. Vagal maneuvers are recommended for acute treatment in pregnant patients with SVT.235,516 See Online Data Supplement 20. For acute conversion of SVT, vagal maneuvers, including Valsalva and carotid sinus massage, can be performed quickly and should be the first-line intervention to terminate SVT. These maneuvers should be performed with the patient in the supine position. Vagal maneuvers typically will not be effective if the rhythm does not involve the AV node as a requisite component of a reentrant circuit.


Vagal maneuvers typically will not be effective if the rhythm does not involve the AV node as a requisite component of a reentrant circuit. There is no gold standard for proper Valsalva maneuver technique, but in general, the patient raises intrathoracic pressure by bearing down against a closed glottis for 10 to 30 seconds, equivalent to at least 30 Carotid massage is performed after absence of bruit has been confirmed by auscultation, by applying steady pressure over the right or left carotid sinus for 5 to 10 seconds.83,84 Another vagal maneuver based on the classic diving reflex consists of applying an ice-cold, wet towel to the ; in a laboratory setting, facial immersion in water at 10 C (50 F) has proved effective in terminating tachycardia, as well.86 One study involving 148 nonpregnant patients with SVT demonstrated that Valsalva was more successful than carotid sinus massage, and switching from 1 technique to the other resulted in an overall success rate of 27.7%.82 The practice of applying pressure to the eyeball is potentially dangerous and has been abandoned. I C-LD 2. Adenosine is recommended for acute treatment in pregnant patients with SVT.516 See Online Data Supplement 20. When vagal maneuvers fail to terminate SVT, adenosine is a first-line drug option for pregnant patients.516 Adverse effects to the fetus would not be expected, given that it is unlikely the drug will reach the fetal circulation because of adenosine s short half-life.517 Maternal side effects, such as chest discomfort and flushing, are usually transient. The initial dose for adenosine is 6-mg rapid bolus IV. If this is ineffective, up to 2 subsequent infusions of 12 mg may be administered.


If this is ineffective, up to 2 subsequent infusions of 12 mg may be administered. Higher doses of adenosine may be necessary in some cases; safe administration of up to 24 mg has been reported.518 I C-LD Synchronized cardioversion is recommended for acute treatment in pregnant patients with hemodynamically unstable SVT when pharmacological therapy is ineffective or contraindicated.516 See Online Data Supplement 20. Synchronized cardioversion has been reported to be safe at all stages of pregnancy. The electrode pads should be applied such that the energy source and trajectory are directed away from the uterus.519 Fetal monitoring during cardioversion (if time allows) and during the immediate postcardioversion period is recommended.519 Energy dosing for pregnant patients should be the same as in nonpregnant patients.520 9.3.2. Ongoing Management: Recommendations IIa C-LD Intravenous metoprolol or propranolol is reasonable for acute treatment in pregnant patients with SVT when adenosine is ineffective or contraindicated.516 See Online Data Supplement 20. Beta-adrenergic blocking drugs are considered the first-line option for a variety of arrhythmias in pregnancy because there are extensive reports on their safe use from treating a variety of maternal conditions over many decades. A slow infusion would be less likely to cause IIb C-LD Intravenous verapamil may be reasonable for acute treatment in pregnant patients with SVT when adenosine and beta blockers are ineffective or contraindicated.516 See Online Data Supplement 20. Intravenous verapamil has been used effectively for the acute treatment of SVT in pregnant women; however, there is a higher risk of maternal hypotension with intravenous verapamil than with adenosine.516 Reports on diltiazem use for acute SVT termination in pregnancy are more limited than for verapamil, yet similar effects are expected.517 IIb C-LD 2. Intravenous procainamide may be reasonable for acute treatment in pregnant patients with SVT.522 See Online Data Supplement 20.


Intravenous procainamide may be reasonable for acute treatment in pregnant patients with SVT.522 See Online Data Supplement 20. Intravenous procainamide has been used safely to treat a variety of maternal and fetal supraventricular and ventricular arrhythmias and can be effective when used for acute conversion.517,522 Procainamide is generally best avoided as long-term therapy because it can cause a lupus- like syndrome, unless other options are contraindicated or ineffective. IIb C-LD Intravenous amiodarone may be considered for acute treatment in pregnant patients with potentially life-threatening SVT when other therapies are ineffective or contraindicated.517,523 See Online Data Supplement 20. Although intravenous amiodarone has been administered safely during pregnancy, multiple adverse effects to the fetus have also been An important concern is the possibility of fetal hypothyroidism, reported in approximately 17% of cases.517,523 With an intravenous infusion for short-term use, side effects would be less of a concern, given that most toxicities are related to cumulative drug dose. Recommendations for Acute Treatment of SVT in Pregnant Patients (Continued) COR LOE Recommendations Recommendations for Ongoing Management of SVT in Pregnant Patients COR LOE Recommendations IIa C-LD The following drugs, alone or in combination, can be effective for ongoing management in pregnant patients with highly symptomatic SVT: See Online Data Supplement 20. If possible, antiarrhythmic drugs should be avoided in the first trimester, when risk of congenital malformations is greatest. Almost no reports exist on the use of newer antiarrhythmic drugs (such as dofetilide) during pregnancy, yet their use may be justified if the benefits outweigh the risk. The lowest recommended dose should be used initially, with dose adjustments made according to clinical response.


The lowest recommended dose should be used initially, with dose adjustments made according to clinical response. For oral chronic prophylaxis, drugs such as metoprolol, propranolol, and digoxin are considered safe first-line agents because of their longer record of safety, yet caution is advised, given that therapy with beta blockers has been associated with intrauterine growth retardation.517,524 This effect appears to be especially pronounced with atenolol, especially in mothers who received atenolol earlier in gestational age and who were treated for longer duration.525 Flecainide and propafenone have been used effectively to treat a variety of maternal and fetal tachycardias, yet they are reserved for patients who have no underlying structural heart disease or ischemic heart disease.113 IIb C-LD Catheter ablation may be reasonable in pregnant patients with highly symptomatic, recurrent, drug-refractory SVT with efforts toward minimizing radiation exposure.526,527 See Online Data Supplement 20.


For oral chronic prophylaxis, drugs such as metoprolol, propranolol, and digoxin are considered safe first-line agents because of their longer record of safety, yet caution is advised, given that therapy with beta blockers has been associated with intrauterine growth retardation.517,524 This effect appears to be especially pronounced with atenolol, especially in mothers who received atenolol earlier in gestational age and who were treated for longer duration.525 Flecainide and propafenone have been used effectively to treat a variety of maternal and fetal tachycardias, yet they are reserved for patients who have no underlying structural heart disease or ischemic heart disease.113 IIb C-LD Catheter ablation may be reasonable in pregnant patients with highly symptomatic, recurrent, drug-refractory SVT with efforts toward minimizing radiation exposure.526,527 See Online Data Supplement 20. The risk of radiation exposure to the fetus is a concern with catheter ablation in pregnant patients, because high-dose ionizing radiation has been linked to excess malignancy and congenital malformations.528 However, the fetal radiation dose for most common cardiovascular interventions is not likely to exceed the 50-mGy negligible-risk threshold dose for excess malignancy.529 One study that used phantoms to simulate pregnancy estimated a low lifetime risk of malignancies from radiation exposure to the conceptus during a typical ablation procedure.527 Furthermore, with current technologies such as electroanatomic mapping systems, catheter ablation procedures using minimal or even zero fluoroscopy have been described in pregnant women.526 Thus, if a catheter ablation procedure is required in a pregnant woman, radiation-reduction technologies should be used, and the procedure should be avoided in the first trimester when the teratogenic risk is greatest.528 Of note, shielding the fetus by covering the mother with a lead apron does not eliminate radiation to the fetus because most of the radiation to the fetus comes from scatter.


The risk of radiation exposure to the fetus is a concern with catheter ablation in pregnant patients, because high-dose ionizing radiation has been linked to excess malignancy and congenital malformations.528 However, the fetal radiation dose for most common cardiovascular interventions is not likely to exceed the 50-mGy negligible-risk threshold dose for excess malignancy.529 One study that used phantoms to simulate pregnancy estimated a low lifetime risk of malignancies from radiation exposure to the conceptus during a typical ablation procedure.527 Furthermore, with current technologies such as electroanatomic mapping systems, catheter ablation procedures using minimal or even zero fluoroscopy have been described in pregnant women.526 Thus, if a catheter ablation procedure is required in a pregnant woman, radiation-reduction technologies should be used, and the procedure should be avoided in the first trimester when the teratogenic risk is greatest.528 Of note, shielding the fetus by covering the mother with a lead apron does not eliminate radiation to the fetus because most of the radiation to the fetus comes from scatter. IIb C-LD Oral amiodarone may be considered for ongoing management in pregnant patients when treatment of highly symptomatic, recurrent SVT is required and other therapies are ineffective or contraindicated.517,523 See Online Data Supplement 20. Although oral amiodarone has been administered safely during pregnancy, multiple adverse effects to the fetus have also been reported.523 An important concern is the possibility of fetal hypothyroidism, reported in approximately 17% of cases.517,523 Therefore, fetal monitoring for development of goiter with ultrasound and for signs of clinical hypothyroidism is advised. In addition, amiodarone has the potential for direct neurotoxicity, which may lead to neurodevelopmental abnormalities.523 Page et al 2015 ACC/AHA/HRS SVT Guideline e555 9.4. SVT in Older Populations 9.4.1.


In addition, amiodarone has the potential for direct neurotoxicity, which may lead to neurodevelopmental abnormalities.523 Page et al 2015 ACC/AHA/HRS SVT Guideline e555 9.4. SVT in Older Populations 9.4.1. Acute Treatment and Ongoing Management: Recommendation The natural history of SVT is steadily changing because most patients with SVT undergo ablation at a younger age, but in general, the relative proportion of AT is higher in older popu- lations, and AVNRT is more prevalent than AVRT among patients undergoing ablation.49 Atypical atrial flutter and mac- roreentrant AT are on the rise as consequences of increasing AF ablation in this patient population, yet there are limited outcome data from RCTs for this segment of the population. Therapeutic decisions should be balanced between the over- all risks and benefits of the invasive nature of ablation versus long-term commitment to pharmacological therapy. 10. Quality-of-Life Considerations Patients with SVT may experience recurring symptoms that negatively impact their quality of life. Episodes of tachy- cardia can cause lightheadedness and syncope, which can become an obstacle to the performance of usual activities of daily living (eg, driving).72 However, there are minimal data on the effect of treatment on the quality of life for patients with SVT. In 1 study that evaluated patients with SVT who underwent ablation or received medical therapy, questionnaires such as the 36-Item Short-Form Health Survey revealed improved quality-of-life scores in several categories, including physical role functioning (perceived disability from physical limitations), general health percep- tions (perceived physical and mental health), and emotional role functioning (perceived disability from emotional limi- These improvements, measured at 1 to 5 years of follow-up, were greater in patients who underwent abla- tion than in those treated with medical therapy.


In 1 study that evaluated patients with SVT who underwent ablation or received medical therapy, questionnaires such as the 36-Item Short-Form Health Survey revealed improved quality-of-life scores in several categories, including physical role functioning (perceived disability from physical limitations), general health percep- tions (perceived physical and mental health), and emotional role functioning (perceived disability from emotional limi- These improvements, measured at 1 to 5 years of follow-up, were greater in patients who underwent abla- tion than in those treated with medical therapy. Other lit- erature, using domains from the 36-Item Short-Form Health and other quality- of-life questionnaires,544 546 suggests that quality of life is improved after ablation for PSVT. However, these data carry important limitations, par- ticularly a lack of an appropriate control group, small sam- ple sizes, and referral bias. Furthermore, patients affected by PSVT carry different experiences. Therefore, firm con- clusions cannot be drawn about the effect on quality of life provided by medical or ablation therapy, and no recommen- dations are provided. See Online Data Supplement 22 for additional data on quality-of-life considerations. Given the rising costs of health care, there is a growing enthusiasm for incorporating economic appraisals of avail- able therapies and resources into guidelines. The 2014 ACC/AHA Statement on Cost/Value Methodology in Clinical Practice Guidelines and Performance Measures 6 called for development of Level of Value categories to accompany COR and LOE in future guidelines. Although basing recommendations on a cost-effectiveness approach to therapy is an important goal for the current and future healthcare economy, it also poses considerable challenges.


Although basing recommendations on a cost-effectiveness approach to therapy is an important goal for the current and future healthcare economy, it also poses considerable challenges. For example, the cost of therapy, available technology, and practice patterns are highly dynamic, and there may Recommendations for Acute Treatment and Ongoing Management of SVT in Older Populations COR LOE Recommendation I B-NR Diagnostic and therapeutic approaches to SVT should be individualized in patients more than 75 years of age to incorporate age, comorbid illness, physical and cognitive functions, patient preferences, and severity of symptoms.66,67,530 538 See Online Data Supplement 20. Data have consistently demonstrated that ablation is highly successful (>95%) in selected older patients.66,67,531 536 Outcomes from 48 medical centers in Germany were reported among 3234 consecutive patients undergoing AVNRT ablation from 2007 to 2010; of the total, Acute success was achieved in 98.5% of the older patient group, similar to the 2 younger patient groups (98.7% for the group <50 years of age; 98.8% for the group 50 to 75 years of age). In this study, complication rates were low; hemodynamically stable pericardial effusion was observed in 2 of 259 patients (0.8%), and no pacemakers were needed in the older patient group. Similarly, additional studies from older patient cohorts have consistently shown that older patients have more comorbid medical conditions, have a higher incidence of structural heart disease or ischemic heart disease, and have more severe symptoms associated with A few studies have shown that complications may be slightly higher in older patients than in younger patients, although the overall complications are low and acceptable.530,538,539 These ablation outcome data should be balanced with the risks and benefits of pharmacological therapy when therapeutic options are reviewed with older patients. Figure 22. Acute treatment of SVT in ACHD patients.


Similarly, additional studies from older patient cohorts have consistently shown that older patients have more comorbid medical conditions, have a higher incidence of structural heart disease or ischemic heart disease, and have more severe symptoms associated with A few studies have shown that complications may be slightly higher in older patients than in younger patients, although the overall complications are low and acceptable.530,538,539 These ablation outcome data should be balanced with the risks and benefits of pharmacological therapy when therapeutic options are reviewed with older patients. Figure 22. Acute treatment of SVT in ACHD patients. Colors correspond to Class of Recommendation in Table 1; drugs listed alphabetically. *For rhythms that break or recur spontaneously, synchronized cardioversion is not appropriate. ACHD indicates adult congenital heart disease; IV, intravenous; and SVT, supra- ventricular tachycardia. be some cost associated with unintended harm or compli- cations that result from any intervention. Furthermore, the approach toward evaluating the burden of cost in the litera- ture is based on varied perspectives (eg, individual, third party, stakeholder, societal). The small body of literature evaluating cost-effectiveness strategies in PSVT has traditionally centered on an evalua- tion of medical therapy versus catheter ablation. A rigorous cost-effectiveness Markov model was conducted in 2000 to compare radiofrequency ablation to medical management with generic metoprolol from the societal perspective.105 The estimated population consisted of patients with AVNRT (approximately 65%) and AVRT. On the basis of this simula- tion, the authors concluded that, for symptomatic patients with monthly episodes of PSVT, radiofrequency ablation was the more effective and less expensive strategy when compared with medical therapy.


On the basis of this simula- tion, the authors concluded that, for symptomatic patients with monthly episodes of PSVT, radiofrequency ablation was the more effective and less expensive strategy when compared with medical therapy. An observational cohort study of patients with atrial flutter supported early ablation to significantly reduce hospital-based healthcare utilization and the risk of AF.547 These studies, along with other older literature, favor cath- eter ablation over medical therapy as the more cost-effective approach to treating PSVT and atrial flutter. However, the results of these studies were based on cost data and practice patterns that do not apply to the current environment and prac- tice. Therefore, no recommendations are provided. See Online Data Supplement 23 for additional data on cost-effectiveness. 12. Shared Decision Making It is important that the patient be included in clinical decision- making processes, with consideration of his/her preferences and goals for therapy, as well as his/her unique physical, psychological, and social situation. In selected cases, per- sonalized, self-directed interventions can be developed in partnership with the patient, such as vagal maneuvers and pill-in-the-pocket drug therapy. Shared decision making is especially important for patients with SVT. As seen in this guideline, SVT treatment can be nuanced and requires expert knowledge of EP pro- cesses and treatment options. Treatment options are highly specific to the exact type of arrhythmia and can depend on certain characteristics of a particular arrhythmia (eg, whether there is pre-excitation). The various choices for therapy, including drugs, cardioversion, invasive treatment, or a combination thereof, can be confusing to the patient, so a detailed explanation of the benefits and risks must be included in the conversation. Patients are encouraged to ask questions with time allot- ted for caregivers to respond.


Patients are encouraged to ask questions with time allot- ted for caregivers to respond. Providing a relaxed atmosphere, anticipating patient concerns, and encouraging patients to keep a notebook with questions could facilitate productive conversations. It is also important that clinicians use lay terminology to explain treatment options to their patients. This involves a clear explanation of the risks and benefits of each recom- mendation, including how other comorbidities may impact each treatment option. Discussions with other physicians and healthcare providers caring for the patient will provide the broadest picture available. A full discussion about decisions for subsequent care and any further instructions is important to reinforce these issues before the patient leaves the healthcare setting. It is the responsibility of the physician and healthcare team to provide the patient with the best possible understand- ing of all management options in terms of risks, benefits, and potential effects on quality of life. 13. Evidence Gaps and Future Research Needs SVTs, even with the exclusion of AF, are among the most common arrhythmias that require medical interven- tion. The decade before the publication of the 2003 ACC/ AHA/ESC Guidelines for the Management of Patients With was characterized by major shifts in understanding of the mechanism for SVT, as well as a sea change in management (because of catheter abla- tion). Since the early 2000s, there have been many iterative but important advances in pharmacological and invasive management for SVT. Catheter ablation is even better estab- lished, with a high degree of success and low complication rate, especially for the most common types of SVT, such as AVNRT and AVRT. Drug options, on the other hand, are rela- tively unchanged since publication of the 2003 guideline, per- haps relating to ongoing concern about potential adverse side effects of antiarrhythmic agents.


Drug options, on the other hand, are rela- tively unchanged since publication of the 2003 guideline, per- haps relating to ongoing concern about potential adverse side effects of antiarrhythmic agents. Areas of uncertainty remain, including interventions for which advanced technology is less important. For example, vagal maneuvers are recommended in many circumstances as first-line intervention in patients with SVT, but they are often ineffective. Furthermore, there is great variation in the way these maneuvers are administered. Therefore, research on the best technique of vagal maneuvers, with dis- semination of the findings, is necessary. Clinical trials on Figure 23. Ongoing management of SVT in ACHD patients. Colors correspond to Class of Recommendation in Table 1; drugs listed alpha- betically. ACHD indicates adult congenital heart disease; intra-op, intraoperative; pre-op, preopera- tive; and SVT, supraventricular tachycardia. Page et al 2015 ACC/AHA/HRS SVT Guideline e557 antiarrhythmic drugs for SVT have been limited, and data are often extrapolated from studies that primarily focused on management of patients with AF. The efficacy of a variety of drugs is likely to differ according to the tachycardia mech- anism, and therefore differentiating the best drug for each individual arrhythmia is necessary; for example, the efficacy of class III agents might be markedly different in patients with AF than in patients with atrial flutter. Limited data exist on the optimal management of less common types of SVTs, such as junctional tachycardia and multifocal AT. Therefore, in view of significant gaps that remain with regard to opti- mal management of patients with SVT, we must consider the role of electronic medical records, registries, and national datasets to better acquire observational data when trials are not available or feasible. Multicenter registry studies would allow for expansion of our knowledge on the best pharma- cological and nonpharmacological approaches to treat these arrhythmias.


Multicenter registry studies would allow for expansion of our knowledge on the best pharma- cological and nonpharmacological approaches to treat these arrhythmias. In collaboration with national societies, the National Institutes of Health, and the US Food and Drug Administration, registries could be developed across selected centers to gather important information on safety and long- term outcomes where data are lacking (just as such registries are being developed for AF ablation). Mandatory postmarket surveillance data collection on new drugs for SVT could also be considered by the US Food and Drug Administration as a condition for drug approval. The mechanism and primary etiology of IST remains to be defined advances here would provide a first step on finding better therapies for this disorder. It should be noted that medi- cal advances have resulted in an increase in the number of patients with SVT in specific populations, such as in patients after ablation (especially AF), ACHD patients, and patients of advanced age. As the numbers of these often-complicated patients grow, opportunities arise to perform clinical research to guide future recommendations. New pharmacological therapies are needed, especially for SVT in patients for whom ablation is not an option or has been unsuccessful. Newer drugs that selectively target atrial channels currently under investigation for patients with AF should be investigated for management of AT. Both mapping and ablation techniques need to be further investigated to maximize the likelihood of successful ablation with minimal risk. In the outpatient setting, the added value of new personal monitoring and implantable devices needs to be assessed, and studies of the impact of shared decision making with patients on outcomes are needed for personal monitoring innovations. Finally, we encourage investigation of quality-of-life improve- ment strategies, in addition to cost-effectiveness studies, for the management of SVT.


Finally, we encourage investigation of quality-of-life improve- ment strategies, in addition to cost-effectiveness studies, for the management of SVT. Presidents and Staff American College of Cardiology Kim A. Williams, Sr, MD, FACC, FAHA, President Shalom Jacobovitz, Chief Executive Officer William J. Oetgen, MD, MBA, FACC, Executive Vice President, Science, Education, and Quality Amelia Scholtz, PhD, Publications Manager, Science, Education, and Quality American College of Cardiology/American Heart Association Lisa Bradfield, CAE, Director, Guidelines and Clinical Policy Abdul R. Abdullah, MD, Associate Science and Medicine Advisor Alexa Papaila, Project Manager, Science and Clinical Policy American Heart Association Mark A. Creager, MD, FACC, FAHA, President Nancy Brown, Chief Executive Officer Rose Marie Robertson, MD, FAHA, Chief Science Officer Gayle R. Whitman, PhD, RN, FAHA, FAAN, Senior Vice President, Office of Science Operations Marco Di Buono, PhD, Vice President, Science, Research, and Professional Education Jody Hundley, Production Manager, Scientific Publications, Office of Science Operations Acknowledgments We thank Dr. Daniel B. Mark for his invaluable assistance in review- ing studies relating to quality of life and cost-effectiveness. His research and insight informed much of the discussion on these topics. We also thank Dr. Sarah A. Spinler for her contributions with regard to antiarrhythmic drug therapy. References 1. Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, Institute of Medicine (US). Clinical Practice Guidelines We Can Trust. Washington, DC: National Academies Press, 2011. 2. Committee on Standards for Systematic Reviews of Comparative Effectiveness Research, Institute of Medicine (US). Finding What Works in Health Care: Standards for Systematic Reviews. Washington, DC: National Academies Press, 2011. 3. ACCF/AHA Task Force on Practice Guidelines. Methodology Manual and Policies From the ACCF/AHA Task Force on Practice Guidelines. American College of Cardiology and American Heart Association. 2010. Available at: http://assets.cardiosource.com/Methodology_Manual_ for_ACC_AHA_Writing_Committees.pdf and http://my.americanheart. org/idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/ ucm_319826.pdf. Accessed January 23, 2015. 4.


Available at: http://assets.cardiosource.com/Methodology_Manual_ for_ACC_AHA_Writing_Committees.pdf and http://my.americanheart. org/idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/ ucm_319826.pdf. Accessed January 23, 2015. 4. Jacobs AK, Kushner FG, Ettinger SM, et al. ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:268 310. 5. Jacobs AK, Anderson JL, Halperin JL. The evolution and future of ACC/ AHA clinical practice guidelines: a 30-year journey: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130:1208 17. 6. Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. Circulation. 2014;129:2329 45. 7. Halperin JL, Levine GN, Al-Khatib SM. Further evolution of the ACC/ AHA clinical practice guideline recommendation classification system: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2016;133:1426 28. 8. Arnett DK, Goodman RA, Halperin JL, et al. AHA/ACC/HHS strategies to enhance application of clinical practice guidelines in patients with cardiovascular disease and comorbid conditions: from the American Heart Association, American College of Cardiology, and US Department of Health and Human Services. Circulation. 2014;130:1662 7. 9. Al-Khatib SM, Arshad A, Balk EM et al. Risk stratification for arrhyth- mic events in patients with asymptomatic pre-excitation: a systematic review for the 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2016;133:e575 86. 10. January CT, Wann LS, Alpert JS, et al.


2016;133:e575 86. 10. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guide- line for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2014;130:e199 267. 11. Bl mstrom-Lundqvist C, Scheinman MM, Aliot EM, et al. ACC/AHA/ ESC guidelines for the management of patients with supraventricular arrhythmias executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias). Developed in collaboration with NASPE-Heart Rhythm Society. Circulation. 2003;108:1871 1909. 12. Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/ PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2014;130:1749 67. 13. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/ PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012;126:e354 471. 14. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:e521 643. 15.


2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:e521 643. 15. Goff DC Jr., Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129[suppl 2]:S49 73. 16. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:e240 327. 17. Whitlock RP, Sun JC, Fremes SE, et al. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines. Chest. 2012;141:e576S 600S. 18. Camm AJ, Lip GYH, De Caterina R, et al. 2012 Focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719 47. 19. European Heart Rhythm Association, European Association for Cardio- Thoracic Surgery, CammAJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369 429. 20. Epstein AE, DiMarco JP, Ellenbogen KA, et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2013;127:e283 352. 21. Verma A, Cairns JA, Mitchell LB, et al.


2013;127:e283 352. 21. Verma A, Cairns JA, Mitchell LB, et al. 2014 Focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation. Can J Cardiol. 2014;30:1114 30. 22. Cairns JA, Connolly S, McMurtry S, et al. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and sys- temic thromboembolism in atrial fibrillation and flutter. Can J Cardiol. 2011;27:74 90. 23. Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography,American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2011;124:e783 831. 24. Smith SC Jr., Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124:2458 73. 25. Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease). Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society forAdult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2008;118:e714 833. 26. Chobanian AV, Bakris GL, Black HR, et al.


2008;118:e714 833. 26. Chobanian AV, Bakris GL, Black HR, et al. the National High Blood Pressure Education Program Coordinating Committee: seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206 52. 27. PACES/HRS expert consensus statement on the use of catheter ablation in children and patients with congenital heart disease. J Am Coll Cardiol. 2015; IN PRESS. 28. Sheldon RS, Grubb BP, Olshansky B, et al. 2015 Heart Rhythm Society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm. 2015;12:e41 63. 29. Khairy P, Van Hare GF, Balaji S, et al. PACES/HRS expert consensus statement on the recognition and management of arrhythmias in adult con- genital heart disease. Developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Heart Rhythm. 2014;11:e102 65. 30. Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. J Interv Card Electrophysiol. 2012;33:171 257. 31. Field JM, Hazinski MF, Sayre MR, et al. Part 1: executive summary: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2010;122:S640 56. 32. Orejarena LA, Vidaillet H, DeStefano F, et al. Paroxysmal supraven- tricular tachycardia in the general population. J Am Coll Cardiol. 1998;31:150 7. 33. Calkins H, Sousa J, el-Atassi R, et al. Diagnosis and cure of the Wolff- Parkinson-White syndrome or paroxysmal supraventricular tachycardias during a single electrophysiologic test. N Engl J Med. 1991;324:1612 8. 34. Kay GN, Epstein AE, Dailey SM, et al.


1991;324:1612 8. 34. Kay GN, Epstein AE, Dailey SM, et al. Role of radiofrequency ablation in the management of supraventricular arrhythmias: experience in 760 con- secutive patients. J Cardiovasc Electrophysiol. 1993;4:371 89. 35. Lindsay BD, Chung MK, Gamache MC, et al. Therapeutic end points for the treatment of atrioventricular node reentrant tachycardia by catheter- guided radiofrequency current. J Am Coll Cardiol. 1993;22:733 40. 36. Jackman WM, Beckman KJ, McClelland JH, et al. Treatment of supra- ventricular tachycardia due to atrioventricular nodal reentry, by radio- frequency catheter ablation of slow-pathway conduction. N Engl J Med. 1992;327:313 8. 37. Chen SA, Chiang CE, Yang CJ, et al. Accessory pathway and atrioven- tricular node reentrant tachycardia in elderly patients: clinical features, electrophysiologic characteristics and results of radiofrequency ablation. J Am Coll Cardiol. 1994;23:702 8. 38. Rodriguez LM, de Chillou C, Schl pfer J, et al. Age at onset and gen- der of patients with different types of supraventricular tachycardias. Am J Cardiol. 1992;70:1213 5. 39. Wu D, Yeh SJ, Wang CC, et al. A simple technique for selective radio- frequency ablation of the slow pathway in atrioventricular node reentrant tachycardia. J Am Coll Cardiol. 1993;21:1612 21. 40. Clair WK, Wilkinson WE, McCarthy EA, et al. Spontaneous occurrence of symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricu- lar tachycardia in untreated patients. Circulation. 1993;87:1114 22. 41. Wu D, Denes P, Amat-y-Leon F, et al. Clinical, electrocardiographic and electrophysiologic observations in patients with paroxysmal supraventric- ular tachycardia. Am J Cardiol. 1978;41:1045 51. Page et al 2015 ACC/AHA/HRS SVT Guideline e559 42. DiMarco JP, Miles W, Akhtar M, et al. Adenosine for paroxysmal supra- ventricular tachycardia: dose ranging and comparison with verapamil. Assessment in placebo-controlled, multicenter trials. The Adenosine for PSVT Study Group. Ann Intern Med. 1990;113:104 10. 43. Bhandari AK, Anderson JL, Gilbert EM, et al.


1990;113:104 10. 43. Bhandari AK, Anderson JL, Gilbert EM, et al. Correlation of symp- toms with occurrence of paroxysmal supraventricular tachycardia or atrial fibrillation: a transtelephonic monitoring study. The Flecainide Supraventricular Tachycardia Study Group. Am Heart J. 1992;124:381 6. 44. Sintetos AL, Roark SF, Smith MS, et al. Incidence of symptomatic tachy- cardia in untreated patients with paroxysmal supraventricular tachycardia. Arch Intern Med. 1986;146:2205 9. 45. Henthorn RW, Waldo AL, Anderson JL, et al. Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia. The Flecainide Supraventricular Tachycardia Study Group. Circulation. 1991;83:119 25. 46. Dorian P, Naccarelli GV, Coumel P, et al. A randomized comparison of flecainide versus verapamil in paroxysmal supraventricular tachy- cardia. The Flecainide Multicenter Investigators Group. Am J Cardiol. 1996;77:89A 95A. 47. Lu C-W, Wu M-H, Chen H-C, et al. Epidemiological profile of Wolff- Parkinson-White syndrome in a general population younger than 50 years of age in an era of radiofrequency catheter ablation. Int J Cardiol. 2014;174:530 4. 48. Whinnett ZI, Sohaib SMA, Davies DW. Diagnosis and management of supraventricular tachycardia. BMJ. 2012;345:e7769. 49. Porter MJ, Morton JB, Denman R, et al. Influence of age and gender on the mechanism of supraventricular tachycardia. Heart Rhythm. 2004;1:393 6. 50. Campbell RW. Supraventricular tachycardia: occasional nuisance or fre- quent threat? Eur Heart J. 1996; 17 Suppl C:21 5. 51. Cairns CB, Niemann JT. Intravenous adenosine in the emergency depart- ment management of paroxysmal supraventricular tachycardia. Ann Emerg Med. 1991;20:717 21. 52. Goyal R, Zivin A, Souza J, et al. Comparison of the ages of tachy- cardia onset in patients with atrioventricular nodal reentrant tachy- cardia and accessory pathway-mediated tachycardia. Am Heart J. 1996;132:765 7. 53. Maryniak A, Bielawska A, Bieganowska K, et al.


1996;132:765 7. 53. Maryniak A, Bielawska A, Bieganowska K, et al. Does atrioventricular reentry tachycardia (AVRT) or atrioventricular nodal reentry tachycardia (AVNRT) in children affect their cognitive and emotional development? Pediatr Cardiol. 2013;34:893 7. 54. Gonz lez-Torrecilla E, Almendral J, Arenal A, et al. Combined evalu- ation of bedside clinical variables and the electrocardiogram for the differential diagnosis of paroxysmal atrioventricular reciprocating tachycardias in patients without pre-excitation. J Am Coll Cardiol. 2009;53:2353 8. 55. Liu S, Yuan S, Hertervig E, et al. Gender and atrioventricular conduc- tion properties of patients with symptomatic atrioventricular nodal reen- trant tachycardia and Wolff-Parkinson-White syndrome. J Electrocardiol. 2001;34:295 301. 56. Anand RG, Rosenthal GL, Van Hare GF, et al. Is the mechanism of supra- ventricular tachycardia in pediatrics influenced by age, gender or ethnic- ity? Congenit Heart Dis. 2009;4:464 8. 57. ErdoganA, Schulte B, Carlsson J, et al. [Clinical characteristics of patients with AV-nodal reentrant tachycardia (AVNRT): modification by high fre- quency catheter ablation. Study of 748 patients after high frequency cath- eter ablation]. Med Klin (Munich). 2001;96:708 12. 58. Lee SH, Chen SA, Wu TJ, et al. Effects of pregnancy on first onset and symptoms of paroxysmal supraventricular tachycardia. Am J Cardiol. 1995;76:675 8. 59. Walfridsson U, Str mberg A, Janzon M, et al. Wolff-Parkinson-White syndrome and atrioventricular nodal re-entry tachycardia in a Swedish population: consequences on health-related quality of life. Pacing Clin Electrophysiol. 2009;32:1299 306. 60. Cain N, Irving C, Webber S, et al. Natural history of Wolff- Parkinson-White syndrome diagnosed in childhood. Am J Cardiol. 2013;112:961 5. 61. Lessmeier TJ, Gamperling D, Johnson-Liddon V, et al. Unrecognized par- oxysmal supraventricular tachycardia: potential for misdiagnosis as panic disorder. Arch Intern Med. 1997;157:537 43. 62. Laurent G, Leong-Poi H, Mangat I, et al.


1997;157:537 43. 62. Laurent G, Leong-Poi H, Mangat I, et al. Influence of ventriculoatrial tim- ing on hemodynamics and symptoms during supraventricular tachycardia. J Cardiovasc Electrophysiol. 2009;20:176 81. 63. Abe H, Nagatomo T, Kobayashi H, et al. Neurohumoral and hemodynamic mechanisms of diuresis during atrioventricular nodal reentrant tachycar- dia. Pacing Clin Electrophysiol. 1997;20:2783 8. 64. Auricchio A, Klein H, Trappe HJ, et al. Lack of prognostic value of syncope in patients with Wolff-Parkinson-White syndrome. J Am Coll Cardiol. 1991;17:152 8. 65. Drago F, Turchetta A, Calzolari A, et al. Reciprocating supraventricular tachycardia in children: low rate at rest as a major factor related to propen- sity to syncope during exercise. Am Heart J. 1996;132:280 5. 66. Kalusche D, Ott P, Arentz T, et al. AV nodal re-entry tachycardia in elderly patients: clinical presentation and results of radiofrequency catheter abla- tion therapy. Coron Artery Dis. 1998;9:359 63. 67. Haghjoo M, Arya A, Heidari A, et al. Electrophysiologic characteris- tics and results of radiofrequency catheter ablation in elderly patients with atrioventricular nodal reentrant tachycardia. J Electrocardiol. 2007;40:208 13. 68. Leitch JW, Klein GJ, Yee R, et al. Syncope associated with supraventricu- lar tachycardia: an expression of tachycardia rate or vasomotor response? Circulation. 1992;85:1064 71. 69. Razavi M, Luria DM, Jahangir A, et al. Acute blood pressure changes after the onset of atrioventricular nodal reentrant tachycardia: a time-course analysis. J Cardiovasc Electrophysiol. 2005;16:1037 40. 70. Sganzerla P, Fabbiocchi F, Grazi S, et al. Electrophysiologic and hae- modynamic correlates in supraventricular tachycardia. Eur Heart J. 1989;10:32 9. 71. Hamdan MH, Zagrodzky JD, Page RL, et al. Effect of P-wave timing dur- ing supraventricular tachycardia on the hemodynamic and sympathetic neural response. Circulation. 2001;103:96 101. 72.


Effect of P-wave timing dur- ing supraventricular tachycardia on the hemodynamic and sympathetic neural response. Circulation. 2001;103:96 101. 72. Walfridsson U, Walfridsson H. The impact of supraventricular tachycar- dias on driving ability in patients referred for radiofrequency catheter ablation. Pacing Clin Electrophysiol. 2005;28:191 5. 73. Brugada P, Brugada J, Mont L, et al. A new approach to the differential diagnosis of a regular tachycardia with a wide QRS complex. Circulation. 1991;83:1649 59. 74. Vereckei A, Duray G, Sz n si G, et al. New algorithm using only lead aVR for differential diagnosis of wide QRS complex tachycardia. Heart Rhythm. 2008;5:89 98. 75. Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovas- cular life support: 2010 American Heart Association guidelines for cardio- pulmonary resuscitation and emergency cardiovascular care. Circulation. 2010;122:S729 67. 76. Knight BP, Zivin A, Souza J, et al. Use of adenosine in patients hospital- ized in a university medical center. Am J Med. 1998;105:275 80. 77. Willems S, Shenasa M, Borggrefe M, et al. Atrioventricular nodal reentry tachycardia: electrophysiologic comparisons in patients with and without 2:1 infra-His block. Clin Cardiol. 1993;16:883 8. 78. Pava LF, Peraf n P, Badiel M, et al. R-wave peak time at DII: a new cri- terion for differentiating between wide complex QRS tachycardias. Heart Rhythm. 2010;7:922 6. 79. Letsas KP, Weber R, Siklody CH, et al. Electrocardiographic differen- tiation of common type atrioventricular nodal reentrant tachycardia from atrioventricular reciprocating tachycardia via a concealed accessory path- way. Acta Cardiol. 2010;65:171 6. 80. Knight BP, Ebinger M, Oral H, et al. Diagnostic value of tachycardia fea- tures and pacing maneuvers during paroxysmal supraventricular tachycar- dia. J Am Coll Cardiol. 2000;36:574 82. 81. Murman DH, McDonald AJ, Pelletier AJ, et al. US emergency department visits for supraventricular tachycardia, 1993 2003. Acad Emerg Med.


US emergency department visits for supraventricular tachycardia, 1993 2003. Acad Emerg Med. 2007;14:578 81. 82. Lim SH, Anantharaman V, Teo WS, et al. Comparison of treatment of supraventricular tachycardia by Valsalva maneuver and carotid sinus mas- sage. Ann Emerg Med. 1998;31:30 5. 83. Luber S, Brady WJ, Joyce T, et al. Paroxysmal supraventricular tachycar- dia: outcome after ED care. Am J Emerg Med. 2001;19:40 2. 84. Waxman MB, Wald RW, Sharma AD, et al. Vagal techniques for ter- mination of paroxysmal supraventricular tachycardia. Am J Cardiol. 1980;46:655 64. 85. Tav anoglu S, Ozenel E. Ice-water washcloth rather than facial immer- sion (diving reflex) for supraventricular tachycardia in adults. Am J Cardiol. 1985;56:1003. 86. Wayne MA. Conversion of paroxysmal atrial tachycardia by facial im- mersion in ice water. JACEP. 1976;5:434 5. 87. Brady WJ, DeBehnke DJ, Wickman LL, et al. Treatment of out-of-hos- pital supraventricular tachycardia: adenosine vs verapamil. Acad Emerg Med. 1996;3:574 85. 88. Gausche M, Persse DE, Sugarman T, et al. Adenosine for the prehospital treatment of paroxysmal supraventricular tachycardia. Ann Emerg Med. 1994;24:183 9. 89. Madsen CD, Pointer JE, Lynch TG. A comparison of adenosine and vera- pamil for the treatment of supraventricular tachycardia in the prehospital setting. Ann Emerg Med. 1995;25:649 55. 90. McCabe JL, Adhar GC, Menegazzi JJ, et al. Intravenous adenosine in the prehospital treatment of paroxysmal supraventricular tachycardia. Ann Emerg Med. 1992;21:358 61. 91. Rankin AC, Oldroyd KG, Chong E, et al. Value and limitations of ad- enosine in the diagnosis and treatment of narrow and broad complex tachycardias. Br Heart J. 1989;62:195 203. 92. Lim SH, Anantharaman V, Teo WS, et al. Slow infusion of calcium chan- nel blockers compared with intravenous adenosine in the emergency treatment of supraventricular tachycardia. Resuscitation. 2009;80:523 8. 93. Adenoscan IV (adenosine injection) for rapid bolus intravenous use.


93. Adenoscan IV (adenosine injection) for rapid bolus intravenous use. US Food and Drug Administration. 2015. Available at: http://www.access- July 29, 2015. 94. Roth A, Elkayam I, Shapira I, et al. Effectiveness of prehospital syn- chronous direct-current cardioversion for supraventricular tachyar- rhythmias causing unstable hemodynamic states. Am J Cardiol. 2003;91:489 91. 95. Stec S, Kry ski T, Ku akowski P. Efficacy of low energy rectilinear biphasic cardioversion for regular atrial tachyarrhythmias. Cardiol J. 2011;18:33 8. 96. Gupta A, Naik A, Vora A, et al. Comparison of efficacy of intravenous diltiazem and esmolol in terminating supraventricular tachycardia. J Assoc Physicians India. 1999;47:969 72. 97. Lim SH, Anantharaman V, Teo WS. Slow-infusion of calcium channel blockers in the emergency management of supraventricular tachycardia. Resuscitation. 2002;52:167 74. 98. Mauritson DR, Winniford MD, Walker WS, et al. Oral verapamil for paroxysmal supraventricular tachycardia: a long-term, double-blind ran- domized trial. Ann Intern Med. 1982;96:409 12. 99. Winniford MD, Fulton KL, Hillis LD. Long-term therapy of paroxysmal supraventricular tachycardia: a randomized, double-blind comparison of digoxin, propranolol and verapamil. Am J Cardiol. 1984;54:1138 9. 100. Hindricks G. The Multicentre European Radiofrequency Survey (MERFS): complications of radiofrequency catheter ablation of ar- rhythmias. The Multicentre European Radiofrequency Survey (MERFS) Investigators of the Working Group on Arrhythmias of the European Society of Cardiology. Eur Heart J. 1993;14:1644 53. 101. Hindricks G. Incidence of complete atrioventricular block following at- tempted radiofrequency catheter modification of the atrioventricular node in 880 patients. Results of the Multicenter European Radiofrequency Survey (MERFS) The Working Group on Arrhythmias of the European Society of Cardiology. Eur Heart J. 1996;17:82 8. 102. Spector P, Reynolds MR, Calkins H, et al. Meta-analysis of abla- tion of atrial flutter and supraventricular tachycardia. Am J Cardiol. 2009;104:671 7. 103. Calkins H, Yong P, Miller JM, et al.


2009;104:671 7. 103. Calkins H, Yong P, Miller JM, et al. Catheter ablation of accessory path- ways, atrioventricular nodal reentrant tachycardia, and the atrioventricu- lar junction: final results of a prospective, multicenter clinical trial. The Atakr Multicenter Investigators Group. Circulation. 1999;99:262 70. 104. Scheinman MM, Huang S. The 1998 NASPE prospective catheter abla- tion registry. Pacing Clin Electrophysiol. 2000;23:1020 8. 105. Cheng CH, Sanders GD, Hlatky MA, et al. Cost-effectiveness of radio- frequency ablation for supraventricular tachycardia. Ann Intern Med. 2000;133:864 76. 106. Bohnen M, Stevenson WG, Tedrow UB, et al. Incidence and predictors of major complications from contemporary catheter ablation to treat cardiac arrhythmias. Heart Rhythm. 2011;8:1661 6. 107. Tendera M, Wnuk-Wojnar AM, Kulakowski P, et al. Efficacy and safety of dofetilide in the prevention of symptomatic episodes of paroxysmal supraventricular tachycardia: a 6-month double-blind comparison with propafenone and placebo. Am Heart J. 2001;142:93 8. 108. A randomized, placebo-controlled trial of propafenone in the pro- phylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. UK Propafenone PSVT Study Group. Circulation. 1995;92:2550 7. 109. Chimienti M, Cullen MT, Casadei G. Safety of flecainide versus propafenone for the long-term management of symptomatic paroxys- mal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group. Eur Heart J. 1995;16:1943 51. 110. Anderson JL, Platt ML, Guarnieri T, et al. Flecainide acetate for paroxys- mal supraventricular tachyarrhythmias. The Flecainide Supraventricular Tachycardia Study Group. Am J Cardiol. 1994;74:578 84. 111. Pritchett EL, DaTorre SD, Platt ML, et al. Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrilla- tion: dose-response studies. The Flecainide Supraventricular Tachycardia Study Group. J Am Coll Cardiol. 1991;17:297 303. 112. Pritchett EL, McCarthy EA, Wilkinson WE. Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy. Ann Intern Med.


A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy. Ann Intern Med. 1991;114:539 44. 113. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbid- ity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324:781 8. 114. Wanless RS, Anderson K, Joy M, et al. Multicenter comparative study of the efficacy and safety of sotalol in the prophylactic treatment of pa- tients with paroxysmal supraventricular tachyarrhythmias. Am Heart J. 1997;133:441 6. 115. Gambhir DS, Bhargava M, Nair M, et al. Comparison of electrophysi- ologic effects and efficacy of single-dose intravenous and long-term oral amiodarone therapy in patients with AV nodal reentrant tachycardia. Indian Heart J. 1996;48:133 7. 116. Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;289:871 8. 117. Domanovits H, Laske H, Stark G, et al. Adenosine for the manage- ment of patients with tachycardias-a new protocol. Eur Heart J. 1994;15:589 93. 118. Turakhia MP, Santangeli P, Winkelmayer WC, et al. Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study. J Am Coll Cardiol. 2014;64:660 8. 119. Steinwender C, H nig S, Kypta A, et al. Pre-injection of magnesium sul- fate enhances the efficacy of ibutilide for the conversion of typical but not of atypical persistent atrial flutter. Int J Cardiol. 2010;141:260 5. 120. Tercius AJ, Kluger J, Coleman CI, et al. Intravenous magnesium sulfate enhances the ability of intravenous ibutilide to successfully convert atrial fibrillation or flutter. Pacing Clin Electrophysiol. 2007;30:1331 5. 121. P rez FJ, Schubert CM, Parvez B, et al. Long-term outcomes after cath- eter ablation of cavo-tricuspid isthmus dependent atrial flutter: a meta- analysis. Circ Arrhythm Electrophysiol. 2009;2:393 401.


Long-term outcomes after cath- eter ablation of cavo-tricuspid isthmus dependent atrial flutter: a meta- analysis. Circ Arrhythm Electrophysiol. 2009;2:393 401. 122. de Loma-Osorio F, Diaz-Infante E, et al. Spanish Catheter Ablation Registry. 12th Official Report of the Spanish Society of Cardiology Working Group on Electrophysiology and Arrhythmias (2012). Rev Esp Cardiol (Engl Ed). 2013;66:983 92. 123. Chen SA, Chiang CE, Yang CJ, et al. Sustained atrial tachycardia in adult patients. Electrophysiological characteristics, pharmacological response, possible mechanisms, and effects of radiofrequency ablation. Circulation. 1994;90:1262 78. 124. Biviano AB, Bain W, Whang W, et al. Focal left atrial tachycardias not associated with prior catheter ablation for atrial fibrillation: clinical and electrophysiological characteristics. Pacing Clin Electrophysiol. 2012;35:17 27. 125. Kalman JM, Olgin JE, Karch MR, et al. Cristal tachycardias : origin of right atrial tachycardias from the crista terminalis identified by intracar- diac echocardiography. J Am Coll Cardiol. 1998;31:451 9. 126. Kistler PM, Sanders P, Fynn SP, et al. Electrophysiological and electro- cardiographic characteristics of focal atrial tachycardia originating from the pulmonary veins: acute and long-term outcomes of radiofrequency ablation. Circulation. 2003;108:1968 75. 127. Kistler PM, Fynn SP, Haqqani H, et al. Focal atrial tachycardia from the ostium of the coronary sinus: electrocardiographic and electrophysio- logical characterization and radiofrequency ablation. J Am Coll Cardiol. 2005;45:1488 93. 128. Natale A, Breeding L, Tomassoni G, et al. Ablation of right and left ec- topic atrial tachycardias using a three-dimensional nonfluoroscopic map- ping system. Am J Cardiol. 1998;82:989 92. 129. Goldberger J, Kall J, Ehlert F, et al. Effectiveness of radiofrequency catheter ablation for treatment of atrial tachycardia. Am J Cardiol. 1993;72:787 93. 130. Collins KK, Van Hare GF, Kertesz NJ, et al. Pediatric nonpost-operative junctional ectopic tachycardia medical management and interventional therapies. J Am Coll Cardiol. 2009;53:690 7. 131.


Pediatric nonpost-operative junctional ectopic tachycardia medical management and interventional therapies. J Am Coll Cardiol. 2009;53:690 7. 131. Hamdan M, Van Hare GF, Fisher W, et al. Selective catheter ablation of the tachycardia focus in patients with nonreentrant junctional tachycar- dia. Am J Cardiol. 1996;78:1292 7. 132. Law IH, Von Bergen NH, Gingerich JC, et al. Transcatheter cryother- mal ablation of junctional ectopic tachycardia in the normal heart. Heart Rhythm. 2006;3:903 7. Page et al 2015 ACC/AHA/HRS SVT Guideline e561 133. Akar JG, Kok LC, Haines DE, et al. Coexistence of type I atrial flut- ter and intra-atrial re-entrant tachycardia in patients with surgically cor- rected congenital heart disease. J Am Coll Cardiol. 2001;38:377 84. 134. Ja s P, Shah DC, Ha ssaguerre M, et al. Mapping and ablation of left atrial flutters. Circulation. 2000;101:2928 34. 135. Coffey JO, d Avila A, Dukkipati S, et al. Catheter ablation of scar-related atypical atrial flutter. Europace. 2013;15:414 9. 136. Triedman JK, Bergau DM, Saul JP, et al. Efficacy of radiofrequency ablation for control of intraatrial reentrant tachycardia in patients with congenital heart disease. J Am Coll Cardiol. 1997;30:1032 8. 137. Nakagawa H, Shah N, Matsudaira K, et al. Characterization of reentrant circuit in macroreentrant right atrial tachycardia after surgical repair of congenital heart disease: isolated channels between scars allow focal ablation. Circulation. 2001;103:699 709. 138. Chan DP, Van Hare GF, Mackall JA, et al. Importance of atrial flutter isthmus in postoperative intra-atrial reentrant tachycardia. Circulation. 2000;102:1283 9. 139. Stevenson IH, Kistler PM, Spence SJ, et al. Scar-related right atrial macroreentrant tachycardia in patients without prior atrial surgery: electroanatomic characterization and ablation outcome. Heart Rhythm. 2005;2:594 601. 140. Baker BM, Lindsay BD, Bromberg BI, et al.


2005;2:594 601. 140. Baker BM, Lindsay BD, Bromberg BI, et al. Catheter ablation of clini- cal intraatrial reentrant tachycardias resulting from previous atrial sur- gery: localizing and transecting the critical isthmus. J Am Coll Cardiol. 1996;28:411 7. 141. Haines DE, Beheiry S, Akar JG, et al. Heart Rythm Society expert con- sensus statement on electrophysiology laboratory standards: process, pro- tocols, equipment, personnel, and safety. Heart Rhythm. 2014;11:e9 51. 142. Knight BP, Zivin A, Souza J, et al. A technique for the rapid diagnosis of atrial tachycardia in the electrophysiology laboratory. J Am Coll Cardiol. 1999;33:775 81. 143. Horowitz LN, Kay HR, Kutalek SP, et al. Risks and complications of clinical cardiac electrophysiologic studies: a prospective analysis of 1,000 consecutive patients. J Am Coll Cardiol. 1987;9:1261 8. 144. Asirvatham S, Narayan O. Advanced catheter mapping and navigation system. In: Huang SW, Wood M, editors. Catheter Ablation of Cardiac Arrhythmias. Philadelphia, PA: Saunders/Elsevier, 2006:135 61. 145. Sporton SC, Earley MJ, Nathan AW, et al. Electroanatomic versus fluoro- scopic mapping for catheter ablation procedures: a prospective random- ized study. J Cardiovasc Electrophysiol. 2004;15:310 5. 146. Kopelman HA, Prater SP, Tondato F, et al. Slow pathway catheter ab- lation of atrioventricular nodal re-entrant tachycardia guided by elec- troanatomical mapping: a randomized comparison to the conventional approach. Europace. 2003;5:171 4. 147. Hindricks G, Willems S, Kautzner J, et al. Effect of electroanatomically guided versus conventional catheter ablation of typical atrial flutter on the fluoroscopy time and resource use: a prospective randomized multi- center study. J Cardiovasc Electrophysiol. 2009;20:734 40. 148. Mah DY, Miyake CY, Sherwin ED, et al. The use of an integrated electro- anatomic mapping system and intracardiac echocardiography to reduce radiation exposure in children and young adults undergoing ablation of supraventricular tachycardia. Europace. 2014;16:277 83. 149.


The use of an integrated electro- anatomic mapping system and intracardiac echocardiography to reduce radiation exposure in children and young adults undergoing ablation of supraventricular tachycardia. Europace. 2014;16:277 83. 149. Alvarez M, Tercedor L, Almansa I, et al. Safety and feasibility of catheter ablation for atrioventricular nodal re-entrant tachycardia without fluoro- scopic guidance. Heart Rhythm. 2009;6:1714 20. 150. Casella M, Pelargonio G, Dello RA, et al. Near-zero fluoroscopic ex- posure in supraventricular arrhythmia ablation using the EnSite NavX mapping system: personal experience and review of the literature. J Interv Card Electrophysiol. 2011;31:109 18. 151. Razminia M, Manankil MF, Eryazici PLS, et al. Nonfluoroscopic cath- eter ablation of cardiac arrhythmias in adults: feasibility, safety, and ef- ficacy. J Cardiovasc Electrophysiol. 2012;23:1078 86. 152. Earley MJ, Showkathali R, Alzetani M, et al. Radiofrequency ablation of arrhythmias guided by non-fluoroscopic catheter location: a prospective randomized trial. Eur Heart J. 2006;27:1223 9. 153. Xu D, Yang B, Shan Q, et al. Initial clinical experience of remote magnetic navigation system for catheter mapping and ablation of supraventricular tachycardias. J Interv Card Electrophysiol. 2009;25:171 4. 154. Sommer P, Wojdyla-Hordynska A, Rolf S, et al. Initial experience in ab- lation of typical atrial flutter using a novel three-dimensional catheter tracking system. Europace. 2013;15:578 81. 155. Cummings JE, Pacifico A, Drago JL, et al. Alternative energy sources for the ablation of arrhythmias. Pacing Clin Electrophysiol. 2005;28:434 43. 156. Hanninen M,Yeung-Lai-Wah N, Massel D, et al. Cryoablation versus RF ablation forAVNRT: a meta-analysis and systematic review. J Cardiovasc Electrophysiol. 2013;24:1354 60. 157. Friedman PL, Dubuc M, Green MS, et al. Catheter cryoablation of su- praventricular tachycardia: results of the multicenter prospective frosty trial. Heart Rhythm. 2004;1:129 38. 158. Rodriguez-Entem FJ, Exp sito V, Gonzalez-Enriquez S, et al.


158. Rodriguez-Entem FJ, Exp sito V, Gonzalez-Enriquez S, et al. Cryoablation versus radiofrequency ablation for the treatment of atrio- ventricular nodal reentrant tachycardia: results of a prospective random- ized study. J Interv Card Electrophysiol. 2013;36:41 5. 159. Eckhardt LLL, Leal M, Hollis Z, et al. Cryoablation for AVNRT: im- portance of ablation endpoint criteria. J Cardiovasc Electrophysiol. 2012;23:729 34. 160. Olshansky B, Sullivan RM. Inappropriate sinus tachycardia. J Am Coll Cardiol. 2013;61:793 801. 161. Marcus B, Gillette PC, Garson A. Intrinsic heart rate in children and young adults: an index of sinus node function isolated from autonomic control. Am Heart J. 1990;119:911 6. 162. Jose AD, Collison D. The normal range and determinants of the intrinsic heart rate in man. Cardiovasc Res. 1970;4:160 7. 163. Alboni P, Malcarne C, Pedroni P, et al. Electrophysiology of nor- mal sinus node with and without autonomic blockade. Circulation. 1982;65:1236 42. 164. Winum P-F, Cayla G, Rubini M, et al. A case of cardiomyopathy induced by inappropriate sinus tachycardia and cured by ivabradine. Pacing Clin Electrophysiol. 2009;32:942 4. 165. Romeo E, Grimaldi N, Sarubbi B, et al. A pediatric case of cardiomyopa- thy induced by inappropriate sinus tachycardia: efficacy of ivabradine. Pediatr Cardiol. 2011;32:842 5. 166. Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary ar- tery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a ran- domised, double-blind, placebo-controlled trial. Lancet. 2008;372:807 16. 167. Swedberg K, Komajda M, B hm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376:875 85. 168. Cappato R, Castelvecchio S, Ricci C, et al. Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: a prospective, random- ized, placebo-controlled, double-blind, crossover evaluation. J Am Coll Cardiol. 2012;60:1323 9. 169. Benezet-Mazuecos J, Rubio JM, Farr J, et al.


2012;60:1323 9. 169. Benezet-Mazuecos J, Rubio JM, Farr J, et al. Long-term outcomes of iv- abradine in inappropriate sinus tachycardia patients: appropriate efficacy or inappropriate patients. Pacing Clin Electrophysiol. 2013;36:830 6. 170. Ptaszynski P, Kaczmarek K, Ruta J, et al. Metoprolol succinate vs. ivabradine in the treatment of inappropriate sinus tachycardia in pa- tients unresponsive to previous pharmacological therapy. Europace. 2013;15:116 21. 171. Ptaszynski P, Kaczmarek K, Ruta J, et al. Ivabradine in the treatment of inappropriate sinus tachycardia in patients after successful radiofre- quency catheter ablation of atrioventricular node slow pathway. Pacing Clin Electrophysiol. 2013;36:42 9. 172. Ptaszynski P, Kaczmarek K, Ruta J, et al. Ivabradine in combination with metoprolol succinate in the treatment of inappropriate sinus tachycardia. J Cardiovasc Pharmacol Ther. 2013;18:338 44. 173. Cal L, Rebecchi M, Sette A, et al. Efficacy of ivabradine administration in patients affected by inappropriate sinus tachycardia. Heart Rhythm. 2010;7:1318 23. 174. Kaplinsky E, Comes FP, Urondo LSV, et al. Efficacy of ivabradine in four patients with inappropriate sinus tachycardia: a three month-long experience based on electrocardiographic, Holter monitoring, exercise tolerance and quality of life assessments. Cardiol J. 2010;17:166 71. 175. Rakovec P. Treatment of inappropriate sinus tachycardia with ivabradine. Wien Klin Wochenschr. 2009;121:715 8. 176. Zellerhoff S, Hinterseer M, Felix Krull B, et al. Ivabradine in patients with inappropriate sinus tachycardia. Naunyn Schmiedebergs Arch Pharmacol. 2010;382:483 6. 177. Man KC, Knight B, Tse HF, et al. Radiofrequency catheter ablation of inappropriate sinus tachycardia guided by activation mapping. J Am Coll Cardiol. 2000;35:451 7. 178. Lin D, Garcia F, Jacobson J, et al. Use of noncontact mapping and saline-cooled ablation catheter for sinus node modification in medically refractory inappropriate sinus tachycardia. Pacing Clin Electrophysiol. 2007;30:236 42. 179. Lee RJ, Kalman JM, Fitzpatrick AP, et al.


2007;30:236 42. 179. Lee RJ, Kalman JM, Fitzpatrick AP, et al. Radiofrequency catheter modification of the sinus node for inappropriate sinus tachycardia. Circulation. 1995;92:2919 28. 180. Marrouche NF, Beheiry S, Tomassoni G, et al. Three-dimensional nonfluoroscopic mapping and ablation of inappropriate sinus tachycar- dia. Procedural strategies and long-term outcome. J Am Coll Cardiol. 2002;39:1046 54. 181. Callans DJ, Ren JF, Schwartzman D, et al. Narrowing of the superior vena cava-right atrium junction during radiofrequency catheter ablation for inappropriate sinus tachycardia: analysis with intracardiac echocar- diography. J Am Coll Cardiol. 1999;33:1667 70. 182. Frankel DS, Lin D, Anastasio N, et al. Frequent additional tachyar- rhythmias in patients with inappropriate sinus tachycardia undergoing sinus node modification: an important cause of symptom recurrence. J Cardiovasc Electrophysiol. 2012;23:835 9. 183. Takemoto M, MukaiY, Inoue S, et al. Usefulness of non-contact mapping for radiofrequency catheter ablation of inappropriate sinus tachycardia: new procedural strategy and long-term clinical outcome. Intern Med. 2012;51:357 62. 184. Koplan BA, Parkash R, Couper G, et al. Combined epicardial-endocardi- al approach to ablation of inappropriate sinus tachycardia. J Cardiovasc Electrophysiol. 2004;15:237 40. 185. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med. 2001;344:501 9. 186. Steinbeck G, Hoffmann E. True atrial tachycardia. Eur Heart J. 1998; 19 Suppl E:E48 9. 187. Wren C. Incessant tachycardias. Eur Heart J. 1998;19 Suppl E:E54 9. 188. Medi C, Kalman JM, Haqqani H, et al. Tachycardia-mediated cardio- myopathy secondary to focal atrial tachycardia: long-term outcome after catheter ablation. J Am Coll Cardiol. 2009;53:1791 7. 189. Tang CW, Scheinman MM, Van Hare GF, et al. Use of P wave configura- tion during atrial tachycardia to predict site of origin. J Am Coll Cardiol. 1995;26:1315 24. 190. Kistler PM, Roberts-Thomson KC, Haqqani HM, et al.


1995;26:1315 24. 190. Kistler PM, Roberts-Thomson KC, Haqqani HM, et al. P-wave morphol- ogy in focal atrial tachycardia: development of an algorithm to predict the anatomic site of origin. J Am Coll Cardiol. 2006;48:1010 7. 191. Liu X, Dong J, Ho SY, et al. Atrial tachycardia arising adjacent to non- coronary aortic sinus: distinctive atrial activation patterns and anatomic insights. J Am Coll Cardiol. 2010;56:796 804. 192. Morton JB, Sanders P, Das A, et al. Focal atrial tachycardia arising from the tricuspid annulus: electrophysiologic and electrocardiographic char- acteristics. J Cardiovasc Electrophysiol. 2001;12:653 9. 193. Kistler PM, Sanders P, Hussin A, et al. Focal atrial tachycardia arising from the mitral annulus: electrocardiographic and electrophysiologic characterization. J Am Coll Cardiol. 2003;41:2212 9. 194. Gonzalez MD, Contreras LJ, Jongbloed MRM, et al. Left atrial tachy- cardia originating from the mitral annulus-aorta junction. Circulation. 2004;110: 3187 92. 195. Ouyang F, Ma J, Ho SY, et al. Focal atrial tachycardia originating from the non-coronary aortic sinus: electrophysiological characteristics and catheter ablation. J Am Coll Cardiol. 2006;48:122 31. 196. Roberts-Thomson KC, Kistler PM, Haqqani HM, et al. Focal atrial tachycardias arising from the right atrial appendage: electrocardiograph- ic and electrophysiologic characteristics and radiofrequency ablation. J Cardiovasc Electrophysiol. 2007;18:367 72. 197. Walters TE, Kistler PM, Kalman JM. Radiofrequency ablation for atrial tachycardia and atrial flutter. Heart Lung Circ. 2012;21:386 94. 198. Lee G, Sanders P, Kalman JM. Catheter ablation of atrial arrhythmias: state of the art. Lancet. 2012;380:1509 19. 199. Markowitz SM, Nemirovksy D, Stein KM, et al. Adenosine-insensitive focal atrial tachycardia: evidence for de novo micro-re-entry in the hu- man atrium. J Am Coll Cardiol. 2007;49:1324 33. 200. Engelstein ED, Lippman N, Stein KM, et al. Mechanism-specific effects of adenosine on atrial tachycardia. Circulation. 1994;89:2645 54. 201. Coss SF, Steinberg JS.


Mechanism-specific effects of adenosine on atrial tachycardia. Circulation. 1994;89:2645 54. 201. Coss SF, Steinberg JS. Supraventricular tachyarrhythmias involving the sinus node: clinical and electrophysiologic characteristics. Prog Cardiovasc Dis. 1998;41:51 63. 202. Goya M, Iesaka Y, Takahashi A, et al. Radiofrequency catheter ablation for sinoatrial node reentrant tachycardia: electrophysiologic features of ablation sites. Jpn Circ J. 1999;63:177 83. 203. Saoudi N, Cos o F, Waldo A, et al. A classification of atrial flutter and regular atrial tachycardia according to electrophysiological mechanisms and anatomical bases: a statement from a joint expert group from the Working Group of Arrhythmias of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J. 2001;22:1162 82. 204. Gillette PC, Garson A Jr. Electrophysiologic and pharmacologic charac- teristics of automatic ectopic atrial tachycardia. Circulation. 1977;56:571 5. 205. Mehta AV, Sanchez GR, Sacks EJ, et al. Ectopic automatic atrial tachy- cardia in children: clinical characteristics, management and follow-up. J Am Coll Cardiol. 1988;11:379 85. 206. Eidher U, Freihoff F, Kaltenbrunner W, et al. Efficacy and safety of ibu- tilide for the conversion of monomorphic atrial tachycardia. Pacing Clin Electrophysiol. 2006;29:358 62. 207. Markowitz SM, Stein KM, Mittal S, et al. Differential effects of ad- enosine on focal and macroreentrant atrial tachycardia. J Cardiovasc Electrophysiol. 1999;10:489 502. 208. Reisinger J, Gstrein C, Winter T, et al. Optimization of initial energy for cardioversion of atrial tachyarrhythmias with biphasic shocks. Am J Emerg Med. 2010;28:159 65. 209. Kunze KP, Kuck KH, Schl ter M, et al. Effect of encainide and fle- cainide on chronic ectopic atrial tachycardia. J Am Coll Cardiol. 1986;7:1121 6. 210. Creamer JE, Nathan AW, Camm AJ. Successful treatment of atrial tachy- cardias with flecainide acetate. Br Heart J. 1985;53:164 6. 211. von Bernuth G, Engelhardt W, Kramer HH, et al.


211. von Bernuth G, Engelhardt W, Kramer HH, et al. Atrial automatic tachy- cardia in infancy and childhood. Eur Heart J. 1992;13:1410 5. 212. Lucet V, Do Ngoc D, Fidelle J, et al. [Anti-arrhythmia efficacy of propafenone in children. Apropos of 30 cases]. Arch Mal Coeur Vaiss. 1987;80:1385 93. 213. Heusch A, Kramer HH, Krogmann ON, et al. Clinical experience with propafenone for cardiac arrhythmias in the young. Eur Heart J. 1994;15:1050 6. 214. Janousek J, Paul T. Safety of oral propafenone in the treatment of ar- rhythmias in infants and children (European retrospective multicenter study). Working Group on Pediatric Arrhythmias and Electrophysiology of the Association of European Pediatric Cardiologists. Am J Cardiol. 1998;81:1121 4. 215. Colloridi V, Perri C, Ventriglia F, et al. Oral sotalol in pediatric atrial ectopic tachycardia. Am Heart J. 1992;123:254 6. 216. Guccione P, Paul T, Garson A Jr. Long-term follow-up of amiodarone therapy in the young: continued efficacy, unimpaired growth, moderate side effects. J Am Coll Cardiol. 1990;15:1118 24. 217. Coumel P, Fidelle J. Amiodarone in the treatment of cardiac arrhythmias in children: one hundred thirty-five cases. Am Heart J. 1980;100:1063 9. 218. Miyazaki A, Ohuchi H, Kurosaki K, et al. Efficacy and safety of so- talol for refractory tachyarrhythmias in congenital heart disease. Circ J. 2008;72:1998 2003. 219. Kang KT, Etheridge SP, Kantoch MJ, et al. Current management of focal atrial tachycardia in children: a multicenter experience. Circ Arrhythm Electrophysiol. 2014;7:664 70. 220. Kothari SA, Apiyasawat S, Asad N, et al. Evidence supporting a new rate threshold for multifocal atrial tachycardia. Clin Cardiol. 2005;28:561 3. 221. Yokoshiki H, Mitsuyama H, Watanabe M, et al. Swallowing-induced multifocal atrial tachycardia originating from right pulmonary veins. J Electrocardiol. 2011;44:395.e1 5. 222. Marchlinski FE, Miller JM. Atrial arrhythmias exacerbated by theophyl- line.


Marchlinski FE, Miller JM. Atrial arrhythmias exacerbated by theophyl- line. Response to verapamil and evidence for triggered activity in man. Chest. 1985;88:931 4. 223. Wang K, Goldfarb BL, Gobel FL, et al. Multifocal atrial tachycardia. Arch Intern Med. 1977;137:161 4. 224. Bittar G, Friedman HS. The arrhythmogenicity of theophylline. A multi- variate analysis of clinical determinants. Chest. 1991;99:1415 20. 225. Iseri LT, Fairshter RD, Hardemann JL, et al. Magnesium and potassium therapy in multifocal atrial tachycardia. Am Heart J. 1985;110:789 94. 226. Kastor JA. Multifocal atrial tachycardia. N Engl J Med. 1990;322:1713 7. 227. Hazard PB, Burnett CR. Verapamil in multifocal atrial tachycardia. Hemodynamic and respiratory changes. Chest. 1987;91:68 70. 228. Mukerji V, Alpert MA, Diaz-Arias M, et al. Termination and suppres- sion of multifocal atrial tachycardia with verapamil. South Med J. 1987;80:269 70. 229. Arsura EL, Solar M, Lefkin AS, et al. Metoprolol in the treatment of multifocal atrial tachycardia. Crit Care Med. 1987;15:591 4. 230. Hazard PB, Burnett CR. Treatment of multifocal atrial tachycardia with metoprolol. Crit Care Med. 1987;15:20 5. 231. Kouvaras G, Cokkinos DV, Halal G, et al. The effective treat- ment of multifocal atrial tachycardia with amiodarone. Jpn Heart J. 1989;30:301 12. 232. Levine JH, Michael JR, Guarnieri T. Treatment of multifocal atrial tachy- cardia with verapamil. N Engl J Med. 1985;312:21 5. 233. Salerno DM, Anderson B, Sharkey PJ, et al. Intravenous verapamil for treatment of multifocal atrial tachycardia with and without calcium pre- treatment. Ann Intern Med. 1987;107:623 8. Page et al 2015 ACC/AHA/HRS SVT Guideline e563 234. Mehta D, Wafa S, Ward DE, et al. Relative efficacy of various physi- cal manoeuvres in the termination of junctional tachycardia. Lancet. 1988;1:1181 5. 235. Wen ZC, Chen SA, Tai CT, et al.


1988;1:1181 5. 235. Wen ZC, Chen SA, Tai CT, et al. Electrophysiological mechanisms and determinants of vagal maneuvers for termination of paroxysmal supra- ventricular tachycardia. Circulation. 1998;98:2716 23. 236. Glatter KA, Cheng J, Dorostkar P, et al. Electrophysiologic effects of adenosine in patients with supraventricular tachycardia. Circulation. 1999;99:1034 40. 237. Dougherty AH, Jackman WM, Naccarelli GV, et al. Acute conversion of paroxysmal supraventricular tachycardia with intravenous diltiazem. IV Diltiazem Study Group. Am J Cardiol. 1992;70:587 92. 238. Waxman HL, Myerburg RJ, Appel R, et al. Verapamil for control of ven- tricular rate in paroxysmal supraventricular tachycardia and atrial fibril- lation or flutter: a double-blind randomized cross-over study. Ann Intern Med. 1981;94:1 6. 239. Amsterdam EA, Kulcyski J, Ridgeway MG. Efficacy of cardioselective beta-adrenergic blockade with intravenously administered metoprolol in the treatment of supraventricular tachyarrhythmias. J Clin Pharmacol. 1991;31:714 8. 240. Das G, Tschida V, Gray R, et al. Efficacy of esmolol in the treatment and transfer of patients with supraventricular tachyarrhythmias to alternate oral antiarrhythmic agents. J Clin Pharmacol. 1988;28:746 50. 241. Alboni P, Tomasi C, Menozzi C, et al. Efficacy and safety of out-of- hospital self-administered single-dose oral drug treatment in the man- agement of infrequent, well-tolerated paroxysmal supraventricular tachycardia. J Am Coll Cardiol. 2001;37:548 53. 242. Yeh SJ, Lin FC, Chou YY, et al. Termination of paroxysmal supraven- tricular tachycardia with a single oral dose of diltiazem and propranolol. Circulation. 1985;71:104 9. 243. Rinkenberger RL, Prystowsky EN, Heger JJ, et al. Effects of intravenous and chronic oral verapamil administration in patients with supraventricu- lar tachyarrhythmias. Circulation. 1980;62:996 1010. 244. D Este D, Zoppo F, Bertaglia E, et al. Long-term outcome of patients with atrioventricular node reentrant tachycardia. Int J Cardiol. 2007;115:350 3. 245. Langberg JJ, Leon A, Borganelli M, et al.


2007;115:350 3. 245. Langberg JJ, Leon A, Borganelli M, et al. A randomized, prospective comparison of anterior and posterior approaches to radiofrequency cath- eter ablation of atrioventricular nodal reentry tachycardia. Circulation. 1993;87:1551 6. 246. Kalbfleisch SJ, Strickberger SA, Williamson B, et al. Randomized com- parison of anatomic and electrogram mapping approaches to ablation of the slow pathway of atrioventricular node reentrant tachycardia. J Am Coll Cardiol. 1994;23:716 23. 247. Kay GN, Epstein AE, Dailey SM, et al. Selective radiofrequency ablation of the slow pathway for the treatment of atrioventricular nodal reentrant tachycardia. Evidence for involvement of perinodal myocardium within the reentrant circuit. Circulation. 1992;85:1675 88. 248. Bogun F, Knight B, Weiss R, et al. Slow pathway ablation in patients with documented but noninducible paroxysmal supraventricular tachy- cardia. J Am Coll Cardiol. 1996;28:1000 4. 249. O Hara GE, Philippon F, Champagne J, et al. Catheter ablation for car- diac arrhythmias: a 14-year experience with 5330 consecutive patients at the Quebec Heart Institute, Laval Hospital. Can J Cardiol. 2007;23 Suppl B:67B 70B. 250. Gambhir DS, Bhargava M, Arora R, et al. Electrophysiologic effects and therapeutic efficacy of intravenous flecainide for termination of paroxys- mal supraventricular tachycardia. Indian Heart J. 1995;47:237 43. 251. Musto B, Cavallaro C, Musto A, et al. Flecainide single oral dose for management of paroxysmal supraventricular tachycardia in children and young adults. Am Heart J. 1992;124:110 5. 252. Wellens HJ. Should catheter ablation be performed in asymptomatic pa- tients with Wolff-Parkinson-White syndrome? When to perform catheter ablation in asymptomatic patients with a Wolff-Parkinson-White electro- cardiogram. Circulation. 2005;112:2201 7. 253. Munger TM, Packer DL, Hammill SC, et al. A population study of the natural history of Wolff-Parkinson-White syndrome in Olmsted County, Minnesota, 1953 1989. Circulation. 1993;87:866 73. 254. Pappone C, Vicedomini G, Manguso F, et al.


1993;87:866 73. 254. Pappone C, Vicedomini G, Manguso F, et al. Wolff-Parkinson-White syndrome in the era of catheter ablation: insights from a registry study of 2169 patients. Circulation. 2014;130:811 9. 255. Timmermans C, Smeets JL, Rodriguez LM, et al. Aborted sud- den death in the Wolff-Parkinson-White syndrome. Am J Cardiol. 1995;76:492 4. 256. Klein GJ, Bashore TM, Sellers TD, et al. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. N Engl J Med. 1979;301:1080 5. 257. Bromberg BI, Lindsay BD, Cain ME, et al. Impact of clinical history and electrophysiologic characterization of accessory pathways on man- agement strategies to reduce sudden death among children with Wolff- Parkinson-White syndrome. J Am Coll Cardiol. 1996;27:690 5. 258. Santinelli V, Radinovic A, Manguso F, et al. The natural history of asymptomatic ventricular pre-excitation: a long-term prospective follow-up study of 184 asymptomatic children. J Am Coll Cardiol. 2009;53:275 80. 259. Smith GD, Dyson K, Taylor D, et al. Effectiveness of the Valsalva manoeuvre for reversion of supraventricular tachycardia. Cochrane Database Syst Rev. 2013;3:CD009502. 260. Delaney B, Loy J, Kelly A-M. The relative efficacy of adenosine versus verapamil for the treatment of stable paroxysmal supraventricular tachy- cardia in adults: a meta-analysis. Eur J Emerg Med. 2011;18:148 52. 261. Furlong R, Gerhardt RT, Farber P, et al. Intravenous adenosine as first-line prehospital management of narrow-complex tachycardias by EMS personnel without direct physician control. Am J Emerg Med. 1995;13:383 8. 262. Schatz I, Ordog GJ, Karody R, et al. Wolff-Parkinson-White syndrome presenting in atrial fibrillation. Ann Emerg Med. 1987;16:574 8. 263. Mittal S, Ayati S, Stein KM, et al. Transthoracic cardioversion of atrial fibrillation: comparison of rectilinear biphasic versus damped sine wave monophasic shocks. Circulation. 2000;101:1282 7. 264. Glatter KA, Dorostkar PC, Yang Y, et al. Electrophysiological ef- fects of ibutilide in patients with accessory pathways. Circulation. 2001;104:1933 9.


Electrophysiological ef- fects of ibutilide in patients with accessory pathways. Circulation. 2001;104:1933 9. 265. Sellers TD Jr., Campbell RW, Bashore TM, et al. Effects of procain- amide and quinidine sulfate in the Wolff-Parkinson-White syndrome. Circulation. 1977;55:15 22. 266. Huycke EC, Sung RJ, Dias VC, et al. Intravenous diltiazem for termination of reentrant supraventricular tachycardia: a placebo-controlled, randomized, double-blind, multicenter study. J Am Coll Cardiol. 1989;13:538 44. 267. Hamer A, Peter T, Platt M, et al. Effects of verapamil on supraventricular tachycardia in patients with overt and concealed Wolff-Parkinson-White syndrome. Am Heart J. 1981;101:600 12. 268. Hombach V, Braun V, H pp HW, et al. Antiarrhythmic effects of acute beta blockade with atenolol on supraventricular tachycardias at rest and during exercise. Klin Wochenschr. 1981;59:123 33. 269. Morady F, DiCarlo LA Jr., Baerman JM, et al. Effect of propranolol on ventricular rate during atrial fibrillation in the Wolff-Parkinson-White syndrome. Pacing Clin Electrophysiol. 1987;10:492 6. 270. Wellens HJ, Durrer D. Effect of digitalis on atrioventricular conduction and circus-movement tachycardias in patients with Wolff-Parkinson- White syndrome. Circulation. 1973;47:1229 33. 271. Sellers TD Jr., Bashore TM, Gallagher JJ. Digitalis in the pre-ex- citation syndrome. Analysis during atrial fibrillation. Circulation. 1977;56:260 7. 272. Sheinman BD, Evans T. Acceleration of ventricular rate by fibrillation associated with the Wolff-Parkinson-White syndrome. Br Med J (Clin Res Ed). 1982;285:999 1000. 273. Boriani G, Biffi M, Frabetti L, et al. Ventricular fibrillation after intrave- nous amiodarone in Wolff-Parkinson-White syndrome with atrial fibril- lation. Am Heart J. 1996;131:1214 6. 274. Shiraishi H, Ishibashi K, Urao N, et al. Two cases of polymorphic ven- tricular tachycardia induced by the administration of verapamil against paroxysmal supraventricular tachycardia. Intern Med. 2002;41:445 8. 275. Sch tzenberger W, Leisch F, Gmeiner R. Enhanced accessory pathway conduction following intravenous amiodarone in atrial fibrillation. A case report.


Sch tzenberger W, Leisch F, Gmeiner R. Enhanced accessory pathway conduction following intravenous amiodarone in atrial fibrillation. A case report. Int J Cardiol. 1987;16:93 5. 276. Jackman WM, Wang XZ, Friday KJ, et al. Catheter ablation of accessory atrioventricular pathways (Wolff-Parkinson-White syndrome) by radio- frequency current. N Engl J Med. 1991;324:1605 11. 277. Calkins H, Langberg J, Sousa J, et al. Radiofrequency catheter ablation of accessory atrioventricular connections in 250 patients. Abbreviated therapeutic approach to Wolff-Parkinson-White syndrome. Circulation. 1992;85:1337 46. 278. Dagres N, Clague JR, Kottkamp H, et al. Radiofrequency catheter abla- tion of accessory pathways. Outcome and use of antiarrhythmic drugs during follow-up. Eur Heart J. 1999;20:1826 32. 279. Schl pfer J, Fromer M. Late clinical outcome after successful ra- diofrequency catheter ablation of accessory pathways. Eur Heart J. 2001;22:605 9. 280. Belhassen B, Rogowski O, Glick A, et al. Radiofrequency ablation of accessory pathways: a 14 year experience at the Tel Aviv Medical Center in 508 patients. Isr Med Assoc J. 2007;9:265 70. 281. Kugler JD, Danford DA, Deal BJ, et al. Radiofrequency catheter abla- tion for tachyarrhythmias in children and adolescents. The Pediatric Electrophysiology Society. N Engl J Med. 1994;330:1481 7. 282. Kugler JD, Danford DA, Houston K, et al. Radiofrequency cath- eter ablation for paroxysmal supraventricular tachycardia in chil- dren and adolescents without structural heart disease. Pediatric EP Society, Radiofrequency Catheter Ablation Registry. Am J Cardiol. 1997;80:1438 43. 283. Aguinaga L, Primo J, Anguera I, et al. Long-term follow-up in pa- tients with the permanent form of junctional reciprocating tachycar- dia treated with radiofrequency ablation. Pacing Clin Electrophysiol. 1998;21:2073 8. 284. Kang KT, Potts JE, Radbill AE, et al. Permanent junctional reciprocat- ing tachycardia in children: a multicenter experience. Heart Rhythm. 2014;11:1426 32. 285. McClelland JH, Wang X, Beckman KJ, et al.


2014;11:1426 32. 285. McClelland JH, Wang X, Beckman KJ, et al. Radiofrequency catheter ablation of right atriofascicular (Mahaim) accessory pathways guided by accessory pathway activation potentials. Circulation. 1994;89:2655 66. 286. M nnig G, Wasmer K, Milberg P, et al. Predictors of long-term suc- cess after catheter ablation of atriofascicular accessory pathways. Heart Rhythm. 2012;9:704 8. 287. Sakurai M, Yasuda H, Kato N, et al. Acute and chronic effects of vera- pamil in patients with paroxysmal supraventricular tachycardia. Am Heart J. 1983;105:619 28. 288. Hopson JR, Buxton AE, Rinkenberger RL, et al. Safety and utility of fle- cainideacetateintheroutinecareofpatientswithsupraventriculartachyar- rhythmias: results of a multicenter trial. The Flecainide Supraventricular Tachycardia Study Group. Am J Cardiol. 1996;77:72A 82A. 289. Feld GK, Nademanee K, Weiss J, et al. Electrophysiologic basis for the suppression by amiodarone of orthodromic supraventricular tachy- cardias complicating pre-excitation syndromes. J Am Coll Cardiol. 1984;3:1298 307. 290. Feld GK, Nademanee K, Stevenson W, et al. Clinical and electrophysi- ologic effects of amiodarone in patients with atrial fibrillation complicat- ing the Wolff-Parkinson-White syndrome. Am Heart J. 1988;115:102 7. 291. Gemma LW, Steinberg LA, Prystowsky EN, et al. Development of rapid preexcited ventricular response to atrial fibrillation in a patient with in- termittent preexcitation. J Cardiovasc Electrophysiol. 2013;24:347 50. 292. Bauernfeind RA, Wyndham CR, Dhingra RC, et al. Serial electrophysi- ologic testing of multiple drugs in patients with atrioventricular nodal reentrant paroxysmal tachycardia. Circulation. 1980;62:1341 9. 293. Hung JS, Kou HC, Wu D. Digoxin, propranolol, and atrioventricular re- entrant tachycardia in the Wolff-Parkinson-White syndrome. Ann Intern Med. 1982;97:175 82. 294. Sharma AD, Yee R, Guiraudon G, et al. Sensitivity and specificity of invasive and noninvasive testing for risk of sudden death in Wolff- Parkinson-White syndrome. J Am Coll Cardiol. 1987;10:373 81. 295. Gaita F, Giustetto C, Riccardi R, et al.


1987;10:373 81. 295. Gaita F, Giustetto C, Riccardi R, et al. Stress and pharmacologic tests as methods to identify patients with Wolff-Parkinson-White syndrome at risk of sudden death. Am J Cardiol. 1989;64:487 90. 296. Spar DS, Silver ES, Hordof AJ, et al. Relation of the utility of exercise testing for risk assessment in pediatric patients with ventricular preexci- tation to pathway location. Am J Cardiol. 2012;109:1011 4. 297. Wackel P, Irving C,Webber S, et al. Risk stratification inWolff-Parkinson- White syndrome: the correlation between noninvasive and invasive test- ing in pediatric patients. Pacing Clin Electrophysiol. 2012;35:1451 7. 298. Beckman KJ, Gallastegui JL, Bauman JL, et al. The predictive value of electrophysiologic studies in untreated patients with Wolff-Parkinson- White syndrome. J Am Coll Cardiol. 1990;15:640 7. 299. Pappone C, Vicedomini G, Manguso F, et al. Risk of malignant arrhyth- mias in initially symptomatic patients with Wolff-Parkinson-White syn- drome: results of a prospective long-term electrophysiological follow-up study. Circulation. 2012;125:661 8. 300. Rinne C, Klein GJ, Sharma AD, et al. Relation between clinical presenta- tion and induced arrhythmias in the Wolff-Parkinson-White syndrome. Am J Cardiol. 1987;60:576 9. 301. Brembilla-Perrot B, Holban I, Houriez P, et al. Influence of age on the potential risk of sudden death in asymptomatic Wolff-Parkinson-White syndrome. Pacing Clin Electrophysiol. 2001;24:1514 8. 302. Pappone C, Santinelli V, Manguso F, et al. A randomized study of pro- phylactic catheter ablation in asymptomatic patients with the Wolff- Parkinson-White syndrome. N Engl J Med. 2003;349:1803 11. 303. Pappone C, Santinelli V, Rosanio S, et al. Usefulness of invasive elec- trophysiologic testing to stratify the risk of arrhythmic events in as- ymptomatic patients with Wolff-Parkinson-White pattern: results from a large prospective long-term follow-up study. J Am Coll Cardiol. 2003;41:239 44. 304. Epstein AE, Miles WM, Benditt DG, et al.